Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis

Development and Characterization of a Semi-Solid Dosage Form of Meglumine Antimoniate for Topical Treatment of Cutaneous Leishmaniasis

Cutaneous leishmaniasis (CL) is treated with painful intralesional injections of meglumine antimoniate (MA). With the aim of developing an alternative topical treatment for CL, a gel-based formulation with 30% MA was prepared and its physicochemical properties, stability and rheological behavior wer...

Full description

Bibliographic Details
Main Authors: Diana Berenguer, Lilian Sosa, Magdalena Alcover, Marcella Sessa, Lyda Halbaut, Carme Guillén, Roser Fisa, Ana Cristina Calpena-Campmany, Cristina Riera
Format: Article
Language:English
Published: MDPI AG 2019-11-01
Series:Pharmaceutics
Subjects:
<i>leishmania infantum</i>
cutaneous leishmaniasis
meglumine antimoniate
sepigel 305<sup>®</sup>
topical treatment
Online Access:https://www.mdpi.com/1999-4923/11/11/613

Internet

https://www.mdpi.com/1999-4923/11/11/613

Similar Items